Design Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Design Therapeutics (NASDAQ:DSGN) released its quarterly earnings data on Monday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04, Zacks reports.

Design Therapeutics Stock Down 3.9 %

Design Therapeutics stock opened at $4.92 on Monday. Design Therapeutics has a 52 week low of $2.45 and a 52 week high of $7.77. The firm’s 50-day simple moving average is $4.89 and its 200 day simple moving average is $5.36. The firm has a market capitalization of $278.58 million, a PE ratio of -5.79 and a beta of 1.77.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.